Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment.

van Heuckelum M, Mathijssen EG, Vervloet M, Boonen A, Hebing RC, Pasma A, Vonkeman HE, Wenink MH, van den Bemt BJ, van Dijk L.

Patient Prefer Adherence. 2019 Jul 22;13:1199-1211. doi: 10.2147/PPA.S204111. eCollection 2019.

2.

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaeybroeck B, Klaasen R, van Onna M, Bernelot Moens HJ, Visser H, Schilder AM, Kok MR, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

BMC Rheumatol. 2019 Jun 13;3:3. doi: 10.1186/s41927-019-0071-x. eCollection 2019. Erratum in: BMC Rheumatol. 2019 Aug 20;3:35.

3.

Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry.

van de Laar CJ, Oude Voshaar MAH, Vonkeman HE.

BMC Rheumatol. 2019 Apr 29;3:16. doi: 10.1186/s41927-019-0064-9. eCollection 2019.

4.

Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.

Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ.

Clin Rheumatol. 2019 Aug;38(8):2233-2239. doi: 10.1007/s10067-019-04566-6. Epub 2019 Apr 27.

PMID:
31030363
5.

A systematic literature review of patient-reported outcome measures used in gout: an evaluation of their content and measurement properties.

Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Jansen TLTA, Vonkeman HE, van de Laar MAFJ.

Health Qual Life Outcomes. 2019 Apr 11;17(1):63. doi: 10.1186/s12955-019-1125-x.

6.

Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies.

Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ.

Rheumatology (Oxford). 2019 Nov 1;58(11):1928-1934. doi: 10.1093/rheumatology/kez064.

7.

Development and preliminary evaluation of a short self-report measure of generalized pain hypersensitivity.

van Bemmel PF, Voshaar MAO, Klooster PMT, Vonkeman HE, van de Laar MA.

J Pain Res. 2019 Jan 17;12:395-404. doi: 10.2147/JPR.S182287. eCollection 2019.

8.

Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.

Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar MAFJ.

Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402. [Epub ahead of print]

PMID:
30602035
9.

The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group.

Oude Voshaar MAH, Das Gupta Z, Bijlsma JWJ, Boonen A, Chau J, Courvoisier DS, Curtis JR, Ellis B, Ernestam S, Gossec L, Hale C, Hornjeff J, Leung KYY, Lidar M, Mease P, Michaud K, Mody GM, Ndosi M, Opava CH, Pinheiro GRC, Salt M, Soriano ER, Taylor WJ, Voshaar MJH, Weel AEAM, de Wit M, Wulffraat N, van de Laar MAFJ, Vonkeman HE.

Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23799. [Epub ahead of print]

10.

Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric.

Oude Voshaar MAH, Vonkeman HE, Courvoisier D, Finckh A, Gossec L, Leung YY, Michaud K, Pinheiro G, Soriano E, Wulfraat N, Zink A, van de Laar MAFJ.

Qual Life Res. 2019 Jan;28(1):187-197. doi: 10.1007/s11136-018-2007-0. Epub 2018 Oct 13.

11.

Rasch measurement in rheumatoid arthritis: deriving psychometrically optimal measures from the Rasch Everyday Activity Limitation item bank.

Oude Voshaar MAH, Ten Klooster P, Vonkeman HE, van de Laar MAFJ.

Rheumatology (Oxford). 2018 Oct 1;57(10):1761-1768. doi: 10.1093/rheumatology/key154.

PMID:
29939313
12.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

13.

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23.

14.

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.

Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar MAFJ.

Clin Rheumatol. 2018 Aug;37(8):2291-2296. doi: 10.1007/s10067-018-4127-x. Epub 2018 May 2.

15.

Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.

Versteeg GA, Steunebrink LMM, Vonkeman HE, Ten Klooster PM, van der Bijl AE, van de Laar MAFJ.

Clin Rheumatol. 2018 May;37(5):1189-1197. doi: 10.1007/s10067-017-3962-5. Epub 2018 Feb 1.

16.

Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry.

Steunebrink LMM, Versteeg LGA, Vonkeman HE, Ten Klooster PM, Hoekstra M, van de Laar MAFJ.

BMC Rheumatol. 2018 Jan 17;2:1. doi: 10.1186/s41927-018-0009-8. eCollection 2018.

17.

Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, Gabriel SE, Matteson EL, Kvien TK, Douglas K, Sandoo A, Arts E, Wållberg-Jonsson S, Innala L, Karpouzas G, Dessein PH, Tsang L, El-Gabalawy H, Hitchon C, Ramos VP, Yáñez IC, Sfikakis PP, Zampeli E, Gonzalez-Gay MA, Corrales A, Laar MV, Vonkeman HE, Meek I, Semb AG; A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA).

Ann Rheum Dis. 2018 Jan;77(1):48-54. doi: 10.1136/annrheumdis-2017-211735. Epub 2017 Sep 6.

18.

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.

Janssen CA, Jansen TLTA, Oude Voshaar MAH, Vonkeman HE, van de Laar MAFJ.

Rheumatol Int. 2017 Sep;37(9):1435-1440. doi: 10.1007/s00296-017-3777-3. Epub 2017 Jul 26.

19.

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.

Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, Tchetverikov I, Vreugdenhil SA, van Woerkom JM, Goekoop-Ruiterman YPM, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):516-524. doi: 10.1002/acr.23315.

20.

Measuring everyday functional competence using the Rasch assessment of everyday activity limitations (REAL) item bank.

Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ.

Qual Life Res. 2017 Nov;26(11):2949-2959. doi: 10.1007/s11136-017-1627-0. Epub 2017 Jun 21.

21.

Determinants of Perceived Health Nonimprovement in Early Rheumatoid Arthritis Patients With Favorable Treatment Outcomes.

Steunebrink LMM, Oude Voshaar MAH, Taal E, Vonkeman HE, Zijlstra TR, van de Laar MAFJ.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):510-515. doi: 10.1002/acr.23305. Epub 2018 Mar 7.

22.

Measuring Disease Exacerbation and Flares in Rheumatoid Arthritis: Comparison of Commonly Used Disease Activity Indices and Individual Measures.

Voshaar MAHO, Moghadam MG, Vonkeman HE, Ten Klooster PM, van Schaardenburg D, Tekstra J, Visser H, van de Laar MAFJ, Jansen TL.

J Rheumatol. 2017 Aug;44(8):1118-1124. doi: 10.3899/jrheum.160915. Epub 2017 May 15.

PMID:
28507187
23.

Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods.

Nota I, Drossaert CHC, Melissant HC, Taal E, Vonkeman HE, Haagsma CJ, van de Laar MAFJ.

BMC Med Inform Decis Mak. 2017 Apr 26;17(1):51. doi: 10.1186/s12911-017-0433-5.

24.

The added value of synovial fluid centrifugation for monosodium urate and calcium pyrophosphate crystal detection.

Boumans D, Hettema ME, Vonkeman HE, Maatman RG, van de Laar MA.

Clin Rheumatol. 2017 Jul;36(7):1599-1605. doi: 10.1007/s10067-017-3633-6. Epub 2017 Apr 19.

PMID:
28424907
25.

Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs.

Nota I, Drossaert CH, Taal E, Vonkeman HE, Haagsma CJ, van de Laar MA.

Arthritis Res Ther. 2016 Oct 28;18(1):252.

26.

Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.

Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, Vonkeman HE, Adang E, van de Laar MA, van Riel PL.

J Rheumatol. 2016 Oct;43(10):1787-1794. Epub 2016 Aug 1.

PMID:
27481900
27.

Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology.

Oude Voshaar MA, Schenk O, Ten Klooster PM, Vonkeman HE, Bernelot Moens HJ, Boers M, van de Laar MA.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1206-10. doi: 10.1002/acr.22793.

28.

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.

Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2016 Aug;68(8):1810-7. doi: 10.1002/art.39626.

29.

Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.

Steunebrink LM, Vonkeman HE, ten Klooster PM, Hoekstra M, van Riel PL, van de Laar MA.

Clin Rheumatol. 2016 Mar;35(3):609-15. doi: 10.1007/s10067-016-3191-3. Epub 2016 Feb 6.

30.

Construct Validation of a Multidimensional Computerized Adaptive Test for Fatigue in Rheumatoid Arthritis.

Nikolaus S, Bode C, Taal E, Vonkeman HE, Glas CA, van de Laar MA.

PLoS One. 2015 Dec 28;10(12):e0145008. doi: 10.1371/journal.pone.0145008. eCollection 2015.

31.

Measuring the Therapeutic Relationship in Internet-Based Interventions.

Ferwerda M, van Beugen S, van Riel PC, van de Kerkhof PC, de Jong EM, Smit JV, Zeeuwen-Franssen ME, Kroft EB, Visser H, Vonkeman HE, Creemers MC, van Middendorp H, Evers AW.

Psychother Psychosom. 2016;85(1):47-9. doi: 10.1159/000435958. Epub 2015 Nov 27. No abstract available.

PMID:
26610272
32.

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry.

Manders SH, van de Laar MA, Rongen-van Dartel SA, Bos R, Visser H, Brus HL, Jansen T, Vonkeman HE, van Riel PL, Kievit W.

RMD Open. 2015 Oct 8;1(1):e000147. doi: 10.1136/rmdopen-2015-000147. eCollection 2015.

33.

Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis.

Koop SM, ten Klooster PM, Vonkeman HE, Steunebrink LM, van de Laar MA.

Arthritis Res Ther. 2015 Sep 3;17:237. doi: 10.1186/s13075-015-0761-8.

34.

Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures.

Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Bernelot Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA.

Rheumatology (Oxford). 2015 Dec;54(12):2221-9. doi: 10.1093/rheumatology/kev265. Epub 2015 Jul 29.

PMID:
26224306
35.

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.

Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL.

Arthritis Res Ther. 2015 May 22;17:134. doi: 10.1186/s13075-015-0630-5.

36.

Working mechanism of a multidimensional computerized adaptive test for fatigue in rheumatoid arthritis.

Nikolaus S, Bode C, Taal E, Vonkeman HE, Glas CA, van de Laar MA.

Health Qual Life Outcomes. 2015 Feb 21;13:23. doi: 10.1186/s12955-015-0215-7.

37.

Assessment of fatigue in rheumatoid arthritis: a psychometric comparison of single-item, multiitem, and multidimensional measures.

Oude Voshaar MA, Ten Klooster PM, Bode C, Vonkeman HE, Glas CA, Jansen T, van Albada-Kuipers I, van Riel PL, van de Laar MA.

J Rheumatol. 2015 Mar;42(3):413-20. doi: 10.3899/jrheum.140389. Epub 2015 Jan 15.

PMID:
25593225
38.

Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.

Steunebrink LM, Versteeg GA, Vonkeman HE, Ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PL, van de Laar MA.

Arthritis Res Ther. 2016 Mar 8;18:60. doi: 10.1186/s13075-016-0962-9.

39.

Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice.

Manders SH, Kievit W, Adang E, Jansen TJ, Stolk JN, Visser H, Schilder AM, Vonkeman HE, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2015 Mar;74(3):e24. doi: 10.1136/annrheumdis-2014-207005. Epub 2014 Dec 5. No abstract available.

PMID:
25480886
40.

Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study.

Ten Klooster PM, Vonkeman HE, Oude Voshaar MA, Siemons L, van Riel PL, van de Laar MA.

Rheumatology (Oxford). 2015 Jun;54(6):1080-6. doi: 10.1093/rheumatology/keu449. Epub 2014 Nov 27.

PMID:
25433041
41.

How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis.

Siemons L, Ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA.

BMC Musculoskelet Disord. 2014 Nov 6;15:368. doi: 10.1186/1471-2474-15-368.

42.

Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey.

Nota I, Drossaert CH, Taal E, Vonkeman HE, van de Laar MA.

BMC Musculoskelet Disord. 2014 Oct 4;15:333. doi: 10.1186/1471-2474-15-333.

43.

Relative performance of commonly used physical function questionnaires in rheumatoid arthritis and a patient-reported outcomes measurement information system computerized adaptive test.

Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Krishnan E, van de Laar MA.

Arthritis Rheumatol. 2014 Oct;66(10):2900-8. doi: 10.1002/art.38759.

44.

Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis.

Siemons L, ten Klooster PM, Vonkeman HE, van de Laar MA, Glas CA.

PLoS One. 2014 Jun 23;9(6):e100544. doi: 10.1371/journal.pone.0100544. eCollection 2014.

45.

Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort.

Meek IL, Vonkeman HE, van de Laar MA.

BMC Musculoskelet Disord. 2014 May 23;15:174. doi: 10.1186/1471-2474-15-174.

46.
47.

Impact of patient-accessible electronic medical records in rheumatology: use, satisfaction and effects on empowerment among patients.

van der Vaart R, Drossaert CH, Taal E, Drossaers-Bakker KW, Vonkeman HE, van de Laar MA.

BMC Musculoskelet Disord. 2014 Mar 26;15:102. doi: 10.1186/1471-2474-15-102.

48.

Calibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis.

Oude Voshaar MA, ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA.

PLoS One. 2014 Mar 17;9(3):e92367. doi: 10.1371/journal.pone.0092367. eCollection 2014.

49.

Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker.

Siemons L, Vonkeman HE, ten Klooster PM, van Riel PL, van de Laar MA.

Clin Rheumatol. 2014 Jun;33(6):783-9. doi: 10.1007/s10067-014-2538-x. Epub 2014 Feb 23.

PMID:
24562719
50.

Acceptance of New Technology: A Usability Test of a Computerized Adaptive Test for Fatigue in Rheumatoid Arthritis.

Nikolaus S, Bode C, Taal E, Vonkeman HE, Glas CA, van de Laar MA.

JMIR Hum Factors. 2014 Dec 4;1(1):e4. doi: 10.2196/humanfactors.3424.

Supplemental Content

Loading ...
Support Center